Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRPK1 | Q96SB4 | 3/20 | 0.51 |
| ▸ | SRPK2 | P78362 | 2/20 | 0.51 |
| ▸ | PTK2 | Q05397 | 11/20 | 0.48 |
| ▸ | JAK2 | O60674 | 10/20 | 0.48 |
| ▸ | JAK3 | P52333 | 9/20 | 0.48 |
| ▸ | BRD4 | O60885 | 3/20 | 0.42 |
| ▸ | JAK1 | P23458 | 2/20 | 0.42 |
| ▸ | BRD2 | P25440 | 2/20 | 0.42 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.42 |
| ▸ | BRDT | Q58F21 | 2/20 | 0.42 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.41 |
| ▸ | STAT6 | P42226 | 1/20 | 0.41 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16570103 | 0.92 | PTK2 (0.54) | SRPK1SRPK2PTK2JAK2JAK3 | |
| SCHEMBL17958785 | 0.90 | SRPK1 (0.48) | SRPK1SRPK2PTK2JAK2JAK3 | |
| SCHEMBL16570447 | 0.90 | SRPK1 (0.48) | SRPK1SRPK2PTK2JAK2JAK3 | |
| SCHEMBL16580739 | 0.90 | SRPK1 (0.48) | SRPK1SRPK2PTK2JAK2JAK3 | |
| SCHEMBL16570469 | 0.89 | SRPK1 (0.48) | SRPK1SRPK2PTK2JAK2JAK3 | |
| SCHEMBL16570204 | 0.89 | JAK2 (0.45) | SRPK1SRPK2PTK2JAK2JAK3 | |
| SCHEMBL16570558 | 0.89 | STAT6 (0.42) | SRPK1SRPK2PTK2JAK2JAK3 | |
| SCHEMBL16570515 | 0.88 | PTK2 (0.60) | SRPK1SRPK2PTK2JAK2JAK3 | |
| SCHEMBL16580805 | 0.88 | SRPK2 (0.47) | SRPK1SRPK2PTK2JAK2JAK3 | |
| SCHEMBL16580741 | 0.88 | PTK2 (0.53) | SRPK1SRPK2PTK2JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160222014-A1 | COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS | ASANA BIOSCIENCES, LLC (US) | 2016-08-04 | — | — | US | claimed |
| US-20160222014-A1 | COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS | ASANA BIOSCIENCES, LLC (US) | 2016-08-04 | — | — | US | disclosed |
| WO-2015038417-A1 | COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS | ASANA BIOSCIENCES, LLC (US) | 2015-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160222014-A1 | COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS | SRC, PTK2, FYN | SRPK1 478/4885SRPK2 301/4885PTK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.